CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients)
|
|
- Benjamin Kennedy
- 6 years ago
- Views:
Transcription
1 CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN ADULT CANCER PATIENTS (this guideline excludes haematology patients) 1. Aim/Purpose of this Guideline 1.1. Systemic cancer treatments and immunological therapies can suppress the ability of the bone marrow to respond to infection. Neutropenic sepsis is a potentially fatal complication of anticancer and immunological treatment, particularly chemotherapy Successful management involves immediate assessment and commencement of antibiotics within 60 minutes This guideline aims to improve outcomes for patients at risk of neutropenic sepsis, by providing evidence based recommendations for practice. It is intended for the use by medical nursing and pharmacy staff. 2. The Guidance 2.1. Information, support and training 2.2. Patients receiving anticancer and immunological treatments and their carers should be provided with oral and written information on: Neutropenic sepsis How and when to seek emergency advice How and when to contact 24 hour specialist advice This information is provided via the Chemotherapy contact card, 24 hour contact no: Healthcare professionals and staff involved in the care of patients receiving anticancer treatments should be provided with training on neutropenic sepsis, which should be tailored according to the type of contact. Training will be provided by or under the guidance of the Acute Oncology Nurse Practitioner, this will be provided as face to face sessions held in each area Reducing the risk of septic complications of anticancer treatment 2.5. For adult patients with solid tumours (i.e. non-haematological cancer) in whom significant neutropenia (neutrophil count 0.5x10 9 per litre or lower) is an anticipated consequence of chemotherapy offer prophylaxis with a fluoroquinolone during the expected period of neutropenia ( NICE 2012). The microbiology approved agent for this indication within RCHT is ciprofloxacin Rates of antibiotic resistance and infection patterns should be monitored where patients are having fluoroquinolones for the prophylaxis of neutropenic sepsis. (NICE 2012)
2 2.7. G-CSF (Granulocyte-colony stimulating factor) should not be routinely offered for the prevention of neutropenic sepsis in adults receiving chemotherapy unless an integral part of the chemotherapy regime. (NICE 2012) Neutropenia Neutrophil count 0.5 x 109/L Definition Neutropenia Neutrophil count < 0.5 x 10 9 /L Neutropenic sepsis Neutrophil count < 0.5 X 10 9 /L and either clinical signs of infection or a temperature of 38 o C MASCC risk index Scoring system for the proposed risk index (Multinational association for supportive for identifying low risk neutropenic sepsis care in cancer). patients. Contact information Microbiology Acute Oncology Service bleep Clinical Nurse Specialist via switchboard Oncology consultant on call via switchboard
3 Initial management of oncology chemotherapy related sepsis (possible neutropenic sepsis) For all patients with suspected or confirmed neutropenic sepsis (generally unwell with signs/symptoms of sepsis and/or temperature 38 o C AND history of receiving anticancer therapy ) Assume: Neutropenic sepsis until proven otherwise Urgent Assessment History and examination Observations Venous access (Blood cultures, FBC, U&E, LFT, Lactate, CRP) Sepsis? i.e. signs and symptoms of end organ dysfunction including Altered mental state or Hypoxia (O 2 sats < 94%) or Shock (Systolic BP < 90mmHg)Oliguria YES Resuscitation Immediate 1st Line antibiotics Consider HDU/ITU NO Treat suspected neutropenic sepsis as an acute medical emergency GIVE ANTIBIOTICS IMMEDIATELY Do NOT wait for the FBC Follow RCHT sepsis management guidelines (eg fluid resuscitation etc) Penicillin allergy? Yes history of anaphylaxis No Yes history of non-immediate reaction Ciprofloxacin IV 400mg BD Piperacillin tazobactam IV 4.5g TDS Minor or rash - Ceftazidime IV 2g TDS ESBL carrier use Guided by previous resistance profile Meropenem IV 500mg QDS
4 Management of neutropenic sepsis caused by systemic anti-cancer treatments Confirmed neutropenic sepsis Neutrophil count 0.5 x 10 9 /L and temperature 38º or other signs/symptoms consistent with clinically significant sepsis (if neutrophil count falling and expected to fall to <0.5 also include as neutropenic) Continue antibiotics Refer to RCHT antibiotic policy for Neutropenic sepsis as above Perform RISK ASSESSMENT (MASCC score) Contact Acute Oncology team MASCC (multi-national association for supportive care in cancer) risk assessment used to differentiate between high risk and low risk patients who have already been identified as stable. Characteristic Age >60 years = 0 < 60 years =2 Dehydrated requiring No =3 fluids? Yes = 0 Systolic Blood pressure <90 = 0 > 90 = 5 COPD? Yes = 0 No = 4 Solid tumour or Yes = 4 haematological malignancy No = 0 with no previous fungal infection? Symptoms related to this infective neutropenic episode? Already an inpatient before this episode of infective neutropenia? Total score None = 5 Mild = 5 Moderate = 3 Severe = 0 Yes = 0 No = 3 > 21 = low risk < 21 high risk Score
5 21 or more LOW risk of complications Less than 21 HIGH risk of complications Consider switch to oral antibiotics after hours IV treatment as per the IV to oral switch criteria below. Antibiotic choice guided by culture and sensitivities. If blood culture negative then ciprofloxacin to complete five days. Consider discharge if social and clinical circumstances permit Continue to manage as an inpatient and consider IV to oral switch after hours with choice of agent guided by cultures and sensitivities. If blood culture negative then ciprofloxacin to complete for five days.
6 Does the patient meet the following IV to oral switch criteria? 1. Clinical condition of the patient is improving and haemodynamically stable; HR <100 beats per minute for at least 12 hours with no unexplained tachycardia, Systolic blood pressure >100mmHg, Respiratory rate <20 breaths per minute and no tachypnoea). Afebrile for at least 24 hours (temperature < 38 C oral). Neutrophil count that is rising and above Able to tolerate oral medication and appropriate oral antimicrobial available. Functioning gastrointestinal tract without risk of malabsorption. 3. No haematological malignancy 4. No serious deep-seated infection that requires high-dose IV (see below) Meningitis and CNS infection, osteomyelitis, discitis or mediastinitis, endocarditis or intravascular infection, septic arthritis, Legionella pneumonia, abscess or empyema not drained, exacerbations of cystic fibrosis and bronchiectasis, Staphylococcus aureus bacteraemia, infection of prosthetic device or foreign body, severe soft tissue infections such as necrotising fasciitis. Special points 1. If patient is not neutropenic (neutrophil count >1.7) then treat according to RCHT antibiotic guidelines with antibiotic choice determined by infection source. 2. Ensure robust framework for checking microbiology results if patient discharged before culture results available. 3. Patient should have daily FBC checked until neutrophil count rising and above 0.5 x Ensure the RCHT sepsis pathway is followed for all neutropenic sepsis patients.
7 5.Monitoring compliance and effectiveness This part must provide information on the processes and methodology for monitoring compliance with, and effectiveness of, the policy using the table below. Element to be monitored Lead Tool Frequency Reporting arrangements Appropriate management of those patients identified as neutropneic and those patients identified as not neutropenic. Timely IV to oral switch of antibiotics. Appropriate total antibiotic course lengths. Acute Oncology team supported by the Antibiotic stewardship team Audit tool developed on key parameters within these guidelines Monitored six monthly with a report send to the Infection Control Committee for inclusion in their annual report Antibiotic stewardship management committee, Oncology Governance Group, Medicines Practice Committee and Hospital Infection Control Committee. Acting on recommendations and Lead(s) Change in practice and lessons to be shared Oncology Governance and Medicines Practice Committee a specified timeframe Through the Clinical Oncology governance meetings. 1. Equality and Diversity 1.1. This document complies with the Royal Cornwall Hospitals NHS Trust service Equality and Diversity statement which can be found in the 'Equality, Diversity & Human Rights Policy' or the Equality and Diversity website Equality Impact Assessment The Initial Equality Impact Assessment Screening Form is at Appendix 2.
8 Appendix 1. Governance Information Document Title Date Issued/Approved: 07 July 2017 CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS Date Valid From: 07 July 2017 Date Valid To: 07 July 2020 Directorate / Department responsible (author/owner): Dr Jon McGrane Contact details: Brief summary of contents Appropriate management of neutropenic sepsis in oncology patients Suggested Keywords: Target Audience Executive Director responsible for Policy: Date revised: This document replaces (exact title of previous version): Approval route (names of committees)/consultation: Divisional Manager confirming approval processes Name and Post Title of additional signatories Name and Signature of Divisional/Directorate Governance Lead confirming approval by specialty and divisional management meetings Signature of Executive Director giving approval Publication Location (refer to Policy on Policies Approvals and neutropenia sepsis, oncology, cancer RCHT PCH CFT KCCG Medical Director New Document Clinical oncology governance Medicines Practice Committee Divisional Manager Not Required {Original Copy Signed} Name: {Original Copy Signed} Internet & Intranet Intranet Only
9 Ratification): Document Library Folder/Sub Folder Links to key external standards Related Documents: Training Need Identified? Clinical Oncology Version Control Table Date Version No Summary of Changes Changes Made by (Name and Job Title) V1.0 Version 1 [Please complete all boxes and delete help notes in blue italics including this note] All or part of this document can be released under the Freedom of Information Act 2000 This document is to be retained for 10 years from the date of expiry. This document is only valid on the day of printing Controlled Document This document has been created following the Royal Cornwall Hospitals NHS Trust Policy on Document Production. It should not be altered in any way without the express permission of the author or their Line Manager.
10 Appendix 2. Initial Equality Impact Assessment Form Name of Name of the strategy / policy /proposal / service function to be assessed (hereafter referred to as policy) (Provide brief description): CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS Directorate and service area: Is this a new or existing Policy? Acute Oncology New Name of individual completing Telephone: assessment: Neil Powell 1. Policy Aim* Who is the strategy / policy / proposal / service function aimed at? 2. Policy Objectives* 3. Policy intended Outcomes* Appropriate management of those patients identified as neutropenic and those cancer patients identified as not neutropenic with timely IV to oral switch of antibiotics and appropriate total antibiotic course lengths. 4. *How will you measure the outcome? 5. Who is intended to benefit from the policy? 6a) Is consultation required with the workforce, equality groups, local interest groups etc. around this policy? b) If yes, have these *groups been consulted? C). Please list any groups who have been consulted about this procedure.
11 7. The Impact Please complete the following table. Are there concerns that the policy could have differential impact on: Equality Strands: Yes No Rationale for Assessment / Existing Evidence Age Sex (male, female, trans-gender / gender reassignment) Race / Ethnic communities /groups Disability - learning disability, physical disability, sensory impairment and mental health problems Religion / other beliefs Marriage and civil partnership Pregnancy and maternity Sexual Orientation, Bisexual, Gay, heterosexual, Lesbian You will need to continue to a full Equality Impact Assessment if the following have been highlighted: You have ticked Yes in any column above and No consultation or evidence of there being consultation- this excludes any policies which have been identified as not requiring consultation. or Major service redesign or development 8. Please indicate if a full equality analysis is recommended. Yes No 9. If you are not recommending a Full Impact assessment please explain why. Signature of policy developer / lead manager / director Date of completion and submission 5/9/14
12 Names and signatures of members carrying out the Screening Assessment Human Rights, Equality & Inclusion Lead Keep one copy and send a copy to the Human Rights, Equality and Inclusion Lead c/o Royal Cornwall Hospitals NHS Trust, Human Resources Department, Knowledge Spa, Truro, Cornwall, TR1 3HD A summary of the results will be published on the Trust s web site. Signed Date d
CLINICAL GUIDELINE FOR THE ADMINISTRATION OF NEBULISED PENTAMIDINE Summary. 1.
CLINICAL GUIDELINE FOR THE ADMINISTRATION OF NEBULISED PENTAMIDINE Summary. 1. Patient requires nebulised Pentamidine Ensure equipment listed is available Ensure HEPA filtered room in Haematology Clinic
SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department
Blood Glucose and Hyperglycaemia Management in Hospital for Adults with Diabetes Clinical Guideline V2.0. March 2018
Blood Glucose and Hyperglycaemia Management in Hospital for Adults with Diabetes Clinical Guideline V2.0 March 2018 Page 1 of 8 Summary flow chart for monitoring of blood glucose if >11mmol/L For Adults
Clinical Guideline for Intravenous Opioids for Adults in Recovery Areas The Recovery Protocol
Clinical Guideline for Intravenous Opioids for Adults in Recovery Areas The Recovery Protocol 1. Aim/Purpose of this Guideline 1.1. To Provide safe and efficient administration of Opioids in Recovery.
CLINICAL GUIDELINE FOR THE ADMINISTRATION OF MESNA WITH IFOSFAMIDE AND CYCLOPHOSPHAMIDE Summary.
CLINICAL GUIDELINE FOR THE ADMINISTRATION OF MESNA WITH IFOSFAMIDE AND CYCLOPHOSPHAMIDE Summary. Yes Is patient prescribed ifosfamide or cyclophosphamide >1g/m 2? Chemotherapy prescription on Aria should
28 th September Author Jeremy Gilbert Bariatric Nurse Specialist
POLICY FOR SELF ADMINISTRATION OF CONTINUOUS POSITIVE AIRWAY PRESSURE BY COMPETENT PATIENTS COMING IN FOR METABOLIC AND OBESITY SURGERY (BARIATRIC SURGERY) TO PENDENNIS WARD 28 th September 2014 Author
CLINICAL GUIDELINE FOR THE MANAGEMENT OF BARRETT S OESOPHAGUS Summary.
CLINICAL GUIDELINE FOR THE MANAGEMENT OF BARRETT S OESOPHAGUS Summary. Page 1 of 12 Recurrent LGD at any point- discuss at MDT And consider RFA Patients with LGD should have a repeat endoscopy in 6 months.
DIAGNOSIS AND MANAGEMENT OF PYLORIC STENOSIS IN CHILDREN CLINICAL GUIDELINE V3.0
DIAGNOSIS AND MANAGEMENT OF PYLORIC STENOSIS IN CHILDREN CLINICAL GUIDELINE V3.0 1. Aim/Purpose of this Guideline This guideline is relevant to all medical and nursing staff caring for children with Pyloric
SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN
SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the
PRESEPTAL AND ORBITAL CELLULITIS IN CHILDREN- CLINICAL GUIDELINE V3.0
PRESEPTAL AND ORBITAL CELLULITIS IN CHILDREN- CLINICAL GUIDELINE V3.0 Page 1 of 8 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical and nursing staff caring for a child with Preseptal
METABOLIC BONE DISEASE OF PREMATURITY NEONATAL CLINICAL GUIDELINE V3.0
METABOLIC BONE DISEASE OF PREMATURITY NEONATAL CLINICAL GUIDELINE V3.0 Page 1 of 10 1. Aim/Purpose of this Guideline To provide guidance on the prevention of metabolic bone disease in the neonate. All
1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of acamprosate.
SHARED CARE GUIDELINE FOR ACAMPROSATE 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of
MANAGEMENT OF THE BLADDER IN THE POSTOPERATIVE PERIOD FOLLOWING UNCOMPLICATED GYNAECOLOGICAL SURGERY CLINICAL GUIDELINES
MANAGEMENT OF THE BLADDER IN THE POSTOPERATIVE PERIOD FOLLOWING UNCOMPLICATED GYNAECOLOGICAL SURGERY CLINICAL GUIDELINES 1. Aim/Purpose of this Guideline All clinical staff working in the Division of women,
CLINICAL GUIDELINE FOR INTRAVENOUS FLUID THERAPY FOR ADULTS IN HOSPITAL 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR INTRAVENOUS FLUID THERAPY FOR ADULTS IN HOSPITAL 1. Aim/Purpose of this Guideline 1.1. This guideline contains recommendations about general principles for managing intravenous (IV)
School Hearing Screening Policy
School Hearing Screening Policy V2.1 1st August 2017 Page 1 of 13 Table of Contents 1. Introduction... 3 2. Purpose of this Policy... 3 3. Scope... 3 4. Definitions / Glossary... 3 5. Ownership and Responsibilities...
Start. What is the serum phosphate concentration? Moderate Hypophosphataemia mmol/l. Replace using oral. phosphate. (See section 3.
CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPOPHOSPHATAEMIA IN ADULTS Summary. Key: General Notes GP/SWASFT ED/MAU/SRU/Acute GP/Amb-Care In-patient wards Start What is the serum concentration? Mild Hypophosphataemia
HYPOSPADIAS NEONATAL CLINICAL GUIDELINE. 1. Aim/Purpose of this Guideline. 2. The Guidance
HYPOSPADIAS NEONATAL CLINICAL GUIDELINE 1. Aim/Purpose of this Guideline 1.1. This guideline applies to all staff managing the initial care of infants born with hypospadias. It includes assessment and
CLINICAL GUIDELINE FOR MANAGEMENT OF GALLSTONES PATHOLOGY IN ADULTS
CLINICAL GUIDELINE FOR MANAGEMENT OF GALLSTONES PATHOLOGY IN ADULTS 1. Aim/Purpose of this Guideline This guideline is for the management of gallstones pathology in adults. It has been benchmarked against
CLINICAL GUIDELINE FOR THE MANAGEMENT OF ANAPHYLAXIS IN INFANTS AND CHILDREN UNDER SIXTEEN YEARS OF AGE V3.0
CLINICAL GUIDELINE FOR THE MANAGEMENT OF ANAPHYLAIS IN INFANTS AND CHILDREN UNDER SITEEN YEARS OF AGE V3.0 Page 1 of 16 1. Aim/Purpose of this Guideline 1.1. The purpose of this guideline is to provide
Suspected Pulmonary embolus Ambulatory Pathway. Document Title. Date Issued/Approved: Date Valid From: 11/11/17. Date Valid To: 11/05/18
POLICY UNDER REVIEW Please note that this policy is under review. It does, however, remain current Trust policy subject to any recent legislative changes, national policy instruction (NHS or Department
SHARED CARE GUIDELINE FOR RIFAXIMIN FOR PREVENTING EPISODES OF OVERT HEPATIC ENCEPHALOPATHY IN ADULT PATIENTS 1. Aim/Purpose of this Guideline
SHARED CARE GUIDELINE FOR RIFAXIMIN FOR PREVENTING EPISODES OF OVERT HEPATIC ENCEPHALOPATHY IN ADULT PATIENTS 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy
Fasting for Adults (including Young Adults Age 16+ years) who require Anaesthesia or Intravenous Sedation Clinical Guideline V5.0
Fasting for Adults (including Young Adults Age 16+ years) who require Anaesthesia or Intravenous Sedation November 2018 Summary. Fasting for Adults (including Young Adults Age 16+ years) who require Anaesthesia
Clinical guideline for the introduction of Sacubitril Valsartan in primary and secondary care in Cornwall
Clinical guideline for the introduction of Sacubitril Valsartan in primary and secondary care in Cornwall Page 1 of 15 Summary Patient clinically assessed and reviewed by a Consultant Cardiologist, Cardiology
CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPOKALAEMIA
POLICY UNDER REVIEW Please note that this policy is under review. It does, however, remain current Trust policy subject to any recent legislative changes, national policy instruction (NHS or Department
Protocol for the Management of Neutropenic Sepsis in Adult Patients P
Protocol for the Management of Neutropenic Sepsis in Adult Patients P Version 2 Date April 2015 Review Date April 2016 Author Rachel Onions Change Approver Acute Oncology Team UHMBT. Version 2. CHANGE
GESTATIONAL DIABETES MELLITUS AND SUBSEQUENT MANAGEMENT OF CONFIRMED GESTATIONAL DIABETES MELLITUS (GDM) AND SELECTIVE SCREENING - CLINICAL GUIDELINE
GESTATIONAL DIABETES MELLITUS AND SUBSEQUENT MANAGEMENT OF CONFIRMED GESTATIONAL DIABETES MELLITUS (GDM) AND SELECTIVE SCREENING - CLINICAL GUIDELINE V 1.5 2017 Screening - Clinical Guideline Page 1 of
SHARED CARE GUIDELINE FOR MODAFINIL 1. Aim/Purpose of this Guideline. 2. The Guidance
SHARED CARE GUIDELINE FOR MODAFINIL 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of modafinil.
MANAGEMENT OF NEONATAL HYPOTENSION CLINICAL GUIDELINE
MANAGEMENT OF NEONATAL HYPOTENSION CLINICAL GUIDELINE 1. Aim/Purpose of this Guideline 1.1. To provide guidance on the assessment and management of infants with hypotension. All involved will benefit from
Captopril and Enalapril (Ace Inhibitor) Therapy Clinical Guideline V1.0
Captopril and Enalapril (Ace Inhibitor) Therapy Clinical Guideline V1.0 November 2018 Summary Prescribing, monitoring and administration of Captopril and Enalapril FOR STAFF PATIENTS Medical and Nursing
CLINICAL GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD GLUCOSE LEVELS AND SICK DAYS FOR INSULIN PUMP USERS UNDER THE PAEDIATRIC DIABETES SERVICE. V4.
CLINICAL GUIDELINE FOR THE MANAGEMENT OF HIGH BLOOD GLUCOSE LEVELS AND SICK DAYS FOR INSULIN PUMP USERS UNDER THE PAEDIATRIC DIABETES SERVICE. V4.1 Page 1 of 11 1. Aim/Purpose of this Guideline 1.1. The
Prevention and Treatment of Mucositis in Children and Young People with Cancer Clinical Guideline V3.1 December 2018
Prevention and Treatment of Mucositis in Children and Young People with Cancer Clinical Guideline V3.1 December 2018 1. Aim/Purpose of this Guideline This guideline applies to all medical and nursing staff
A Care Pathway exists for the management of neutropenic fever. Copies of the care pathway document are available in EAU, A&E, Deanesly and CHU.
Subject: Neutropenic Fever Guideline for Junior Doctors Date of Implementation: January 2010 Date of Review: January 2012 Director Responsible for Implementation and Review: Policy location: Consultant
CLINICAL GUIDELINE FOR USE OF A PATIENT CONTROLLED ANALGESIA OR INTRAVENOUS OPIATE INFUSION IN CHILD HEALTH. 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR USE OF A PATIENT CONTROLLED ANALGESIA OR INTRAVENOUS OPIATE INFUSION IN CHILD HEALTH. 1. Aim/Purpose of this Guideline Guideline for children with a Patient Controlled Analgesia
Hypoglycaemia in Adults with Diabetes Clinical Guideline V5.0. March 2018
March 2018 Page 1 of 11 Adult with Diabetes and blood glucose < 4 mmol/l Treatment as per Guideline: Nursing / Clinical Staff Patient reviewed as per guideline guidance notes: Nursing / Clinical Staff
Patient Controlled Analgesia/Intravenous Opiate Infusion in Child Health Clinical Guideline V4.0 October 2018
Patient Controlled Analgesia/Intravenous Opiate Infusion in Child Health Clinical Guideline V4.0 October 2018 Page 1 of 12 1. Aim/Purpose of this Guideline Guideline for children with a Patient Controlled
CLINICAL GUIDELINE FOR THE USE OF PHENYTOIN IN EPILEPSY
This applies to adult patients only CLINICAL GUIDELINE FOR THE USE OF PHENYTOIN IN EPILEPSY Key: General Notes ED/MAU/SRU/Acute GP/Amb-Care GP/SWASFT In-patient wards Start Yes Patient already taking phenytoin?
CLINICAL GUIDELINE FOR MANAGEMENT OF ACUTE CHOLECYSTITIS IN ADULTS
CLINICAL GUIDELINE FOR MANAGEMENT OF ACUTE CHOLECYSTITIS IN ADULTS 1. Aim/Purpose of this Guideline This guideline is for the management of acute cholecystitis in adults. It has been benchmarked against
CLINICAL GUIDELINE FOR NEONATAL BCG VACCINATION V3.0
CLINICAL GUIDELINE FOR NEONATAL BCG VACCINATION V3.0 Page 1 of 11 1. Aim/Purpose of this Guideline 1.1. Tuberculosis is a notifiable disease in the UK and although incidence is low it remains a Public
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway
Reducing the Door to Needle Time for Antibiotics in Suspected Neutropenic Sepsis using a Dedicated Clinical Pathway Dr Alex Williams, Oncology Specialty Doctor. Cheltenham General Hospital Oncology Centre
MUCOSITIS IN CHILDREN AND YOUNG PEOPLE WITH CANCER- CLINICAL GUIDELINE FOR PREVENTION AND TREATMENT V3.0
MUCOSITIS IN CHILDREN AND YOUNG PEOPLE WITH CANCER- CLINICAL GUIDELINE FOR PREVENTION AND TREATMENT V3.0 Page 1 of 10 1. Aim/Purpose of this Guideline 1.1. This guideline applies to all medical and nursing
CLINICAL PROCEDURE FOR THE SAFE REMOVAL OF FEMORAL ARTERIAL SHEATHS USING A DIGITAL APPROACH 1. Aim/Purpose of this Guideline
POLICY UNDER REVIEW Please note that this policy is under review. It does, however, remain current Trust policy subject to any recent legislative changes, national policy instruction (NHS or Department
CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPONATRAEMIA Summary. Start. End. Key: Na + below normal range ( mmol/L) Symptomatic?
CLINICAL GUIDELINE FOR THE MANAGEMENT OF HYPONATRAEMIA Summary Key: General tes ED/MAU/SRU/Acute GP/Amb-Care GP/SWASFT In-patient wards Start Na + below normal range (135 145mmol/L) Refer to endocrinology
Osteoblasts (cells which form new bone) Osteoclasts (cells which break down old bone)
Clinical guideline for the administration of Bisphosphonates and other drugs affecting bone metabolism in Haematology and Oncology patients 1. Aim/Purpose of this Guideline 1.1. To provide education to
Procedure for Subcutaneous Injection of Insulin or GLP1 Analogue in Adults Using a Pen Device V2.0
Procedure for Subcutaneous Injection of Insulin or GLP1 Analogue in Adults Using a Pen Device V2.0 11 October 2017 Table of Contents 1. Introduction.. 3 2. Purpose of this Policy/Procedure. 3 3. Scope
CLINICAL GUIDELINE FOR AN EPIDURAL INFUSION IN CHILD HEALTH 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR AN EPIDURAL INFUSION IN CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. The purpose of this guideline is to provide guidance on caring for children who are receiving epidural
SHARED CARE GUIDELINE FOR MYCOPHENOLATE MOFETIL FOR RHEUMATOLOGY INDICATIONS 1. Aim/Purpose of this Guideline
SHARED CARE GUIDELINE FOR MYCOPHENOLATE MOFETIL FOR RHEUMATOLOGY INDICATIONS 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate
SHARED CARE GUIDELINE FOR TREATMENT OF DEMENTIA 1. Aim/Purpose of this Guideline
POLICY UNDER REVIEW Please note that this policy is under review. It does, however, remain current Trust policy subject to any recent legislative changes, national policy instruction (NHS or Department
PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS
PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS RATIONALE: It is increasingly being recognised that not all neutropenic patients have the same risk of complications during episodes
CLINICAL GUIDELINE FOR THE EVALUATION OF A CHILD PRESENTING WITH FEVER AND SEIZURE V3.0
CLINICAL GUIDELINE FOR THE EVALUATION OF A CHILD PRESENTING WITH FEVER AND SEIZURE V3.0 Clinical Guideline Template Page 1 of 18 Page 1 of 13 1. Aim/Purpose of this Guideline 1.1. This guideline applies
Admission of a Child/Young Person with Cystic Fibrosis Clinical Guideline V3.0 May 2018
Admission of a Child/Young Person with Cystic Fibrosis Clinical Guideline V3.0 May 2018 Page 1 of 16 1. Aim/Purpose of this Guideline This guideline applies to all staff caring for children/young people
CLINICAL GUIDELINE FOR THE MANAGEMENT OF CONVULSIVE STATUS EPILEPTICUS IN CHILDHOOD V3.0
CLINICAL GUIDELINE FOR THE MANAGEMENT OF CONVULSIVE STATUS EPILEPTICUS IN CHILDHOOD V3.0 Clinical Guideline Template Page 1 of 14 1. Aim/Purpose of this Guideline 1.1. This guideline applies to all nursing
NEUTROPENIC SEPSIS IN ADULT PATIENTS. Consultant Clinical Oncologist CLINICAL GUIDELINE
Lancashire Teaching Hospitals NHS Foundation Trust NEUTROPENIC SEPSIS IN ADULT PATIENTS KEY WORDS (To assist in searching for the Guideline on the Intranet suggested minimum 10 words ) REF NO: Neutropenic
The Management of Children and Young People with Newly Presenting Diabetes Clinical Guideline V5.0 December 2018
The Management of Children and Young People with Newly Presenting Diabetes Clinical Guideline December 2018 Summary GP suspects diabetes Under 16 years or still in School Year 11 NO Refer Adults YES Section
DIABETES IN PREGNANCY, TYPE 1 AND TYPE 2 DIABETES MELLITUS (DM), CLINICAL GUIDELINE FOR MIDWIVES V1.4
DIABETES IN PREGNANCY, TYPE 1 AND TYPE 2 DIABETES MELLITUS (DM), CLINICAL GUIDELINE FOR MIDWIVES V1.4 1 1. Aim/Purpose of this Guideline To provide guidance to Midwives, Obstetricians and the Joint Obstetric/Diabetes
Pelvic Inflammatory Disease Clinical Guideline V1.0 February 2019
Pelvic Inflammatory Disease Clinical Guideline V1.0 February 2019 Summary This guideline will provide evidence based guidance on the management of Pelvic Inflammatory Disease A low threshold for empirical
Clinical Guideline for the Management of Pot Operative Atrial Fibrillation
Clinical Guideline for the Management of Pot Operative Atrial Fibrillation 1. Aim/Purpose of this Guideline 1.1. Atrial Fibrillation is the most common cardiac arrhythmia with a prevalence of around 0.5%
Guideline for the Use of Granulocyte Colony Stimulating Factor (G-CSF) for Adults in Oncology and Haematology
(G-CSF) for Adults in Oncology and Haematology For Use in: By: Oncology and Haematology Inpatients and Outpatients Oncologists and Haematologists For: Division responsible for document: Key words: Name
Trust Guideline for the Management of: Condition or Procedure in Adults and / or Children
Trust Guideline for the Management of: Condition or Procedure in Adults and / or Children A clinical guideline recommended For use in: By: For: Division responsible for document: Key words: Name of document
SHARED CARE GUIDELINE FOR LITHIUM. 1. Aim/Purpose of this Guideline. 2. The Guidance
SHARED CARE GUIDELINE FOR LITHIUM 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of lithium.
CARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS
CARE PATHWAY FOR CHILDREN AND YOUNG PERSONS WITH FEBRILE NEUTROPENIA, NEUTROPENIC SEPSIS OR SUSPECTED CENTRAL VENOUS LINE INFECTIONS This Care Pathway has been developed by a multidisciplinary team. It
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE
CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline
Melatonin shared care guideline. Document Title. Corporate: Clinical. Type of document. Brief summary of contents
Document Title Melatonin shared care guideline Type of document Corporate: Clinical Brief summary of contents Executive Director responsible for Policy: Directorate / Department responsible (author/owner):
Neutropenic Sepsis Acute General Management and Support. Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology
Neutropenic Sepsis Acute General Management and Support Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology Who Am I? I am A Medical Oncologist (MCCN) Site specialist
SHARED CARE GUIDELINE FOR CICLOSPORIN IN DERMATOLOGY. 1. Aim/Purpose of this Guideline. 2. The Guidance
SHARED CARE GUIDELINE FOR CICLOSPORIN IN DERMATOLOGY 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration
Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
The Oxford AHSN Sepsis Pathway
From confusion to consensus: The Oxford AHSN Sepsis Pathway Andrew Brent Sepsis Clinical Lead, Oxford AHSN & Oxford University Hospitals NHS Foundation Trust 2013 2014 2015 2016 2017 From: The Third International
North Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance)
North Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance) Introduction OPAT services provide intravenous (IV) antibiotics to patients
PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE. Chief Pharmacist. Chief Pharmacist
REFERENCE NUMBER: PALIPERIDONE LONG ACTING INJECTION PRESCRIBING GUIDELINE AREA: NAME OF RESPONSIBLE COMMITTEE / INDIVIDUAL NAME OF ORIGINATOR / AUTHOR Trust-wide Chief Pharmacist Chief Pharmacist DATE
Spirometry Clinical Guideline V2.0. May 2018
Spirometry Clinical Guideline V2.0 May 2018 Spirometry Clinical Guideline V2.0 1 Summary REFERRAL FOR SPIROMETRY QUALITY ASSURED SPIROMETRY PERFORMED BY TECHNICIAN TRAINED AND ASSESSED AS COMPETENT SPIROMETRY
CLINICAL GUIDELINE FOR THE MANAGEMENT OF VIRAL LARYNGO-TRACHEOBRONCHITIS (CROUP) V3.0
CLINICAL GUIDELINE FOR THE MANAGEMENT OF VIRAL LARYNGO-TRACHEOBRONCHITIS (CROUP) V3.0 Clinical Guideline Template Page 1 of 13 1. Aim/Purpose of this Guideline 1.1. This guideline applies to all nursing
Antimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
Managing Exacerbations of COPD (Version 3.0)
Managing Exacerbations of COPD (Version 3.0) Guideline Readership This guideline is intended for use in patients with a confirmed diagnosis of a chronic obstructive pulmonary disease (COPD) exacerbation.
Haemodialysis central venous catheter-related sepsis management guideline Version 3. NAME M. Letheren Chair Clinical Effectiveness Advisory Group
Lancashire Teaching Hospitals NHS Foundation Trust Haemodialysis central venous catheter-related sepsis management guideline Version 3 AUTHOR APPROVED BY DATE AUTH REF. NO NAME REBG/00018/July12 Michael
MAKING SENSE OF IT ALL AUGUST 17
MAKING SENSE OF IT ALL AUGUST 17 @SepsisUK Dr Ron Daniels B.E.M. CEO, UK Sepsis Trust CEO, Global Sepsis Alliance Special Adviser to WHO SCALE AND BURDEN @sepsisuk Dr Ron Daniels B.E.M. CEO, UK Sepsis
Title Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines. Author s job title
Document Control Title Management of Fever and Neutropenia (Neutropenic Sepsis) in Paediatric Oncology Patients presenting to NDDH Guidelines Author Consultant Microbiologist Consultant Paediatrician Consultant
The Newcastle upon Tyne Hospitals NHS Foundation Trust. Pre-filled Patient Controlled Analgesia (PCA) syringes
The Newcastle upon Tyne Hospitals NHS Foundation Trust Pre-filled Patient Controlled Analgesia (PCA) syringes Version.: 2.2 Effective From: 1 June 2016 Expiry Date: 1 June 2019 Date Ratified: 20 April
Patient Group Directions Policy
Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This
Blood Transfusion Policy for Children and Neonates. November 2017
Blood Transfusion Policy for Children and Neonates V5 November 2017 1. Introduction 3 2. Purpose of this Policy/Procedure 3 3. Scope 3 4. Ownership and Responsibilities 3 4.1. Role of the Managers 3 4.2.
Children who are neutropenic and unwell, even if normothermic, should be assumed to have infection and be treated appropriately.
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
Reference No: SG 23/13
Title: Author(s) Ownership: Approval by: Guidelines for the use of granulocyte colony stimulating factor (GSCF) in adult oncology & malignant haematology patients Paula Scullin, Consultant Medical Oncologist,
CLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR ANTIEMETIC USE IN PAEDIATRIC ONCOLOGY 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical and nursing staff working with paediatric oncology patients. 2. The
Acutely Painful testes
2.0 FINAL Guideline adopted from the Bedside Clinical Guideline Partnership EQUALITY IMPACT The Trust strives to ensure equality of opportunity for all both as a major employer and as a provider of health
Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
Title Use of Pre-Operative Tests for Elective Surgery Guideline. Department. Anaesthetics. Comment / Changes / Approval
Document Control Title Use of Pre-Operative Tests for Elective Surgery Guideline Author Consultant Anaesthetist Author s job title Consultant Anaesthetist Directorate Clinical Support Services Department
NO SMOKING POLICY. Organisational
NO SMOKING POLICY Policy Title State previous title where relevant. State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For clinical policies only - state index
Commissioning Policy. Treatment of Snoring. April 2010
Commissioning Policy Treatment of Snoring April 2010 This commissioning policy applies to patients within: South Worcestershire Clinical Commissioning Group (CCG) Redditch & Bromsgrove Clinical Commissioning
Developed By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
The changing face of
The changing face of sepsis. @SepsisUK Dr Ron Daniels B.E.M. CEO, UK Sepsis Trust CEO, Global Sepsis Alliance Special Adviser (maternal sepsis) to WHO Breast cancer Cognitive impairment Mild 3.8 7.1
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY
PAEDIATRIC FEBRILE NEUTROPENIA CARE PATHWAY Purpose: This document is intended as a guide to the investigation and management of children presenting in Salisbury District Hospital with suspected neutropenic
GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT
GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT Name & Title Of Author: Dr Linda Jewes, Consultant Microbiologist Date Amended: December 2016 Approved by Committee/Group: Drugs & Therapeutics
Specialised Services Commissioning Policy. CP29: Bariatric Surgery
Specialised Services Commissioning Policy CP29: Bariatric Surgery Document Author: Specialist Planner, Cardiothoracic Executive Lead: Director of Planning Approved by: Management Group Issue Date: 12 June
Renal Unit. Catheter Related Bacteraemia Guidelines
Renal Unit Policy Manager Drew Henderson Policy Group Renal Unit Policy Established 21/01/2014 Policy Review Period/Expiry 21/01/2015 Last Updated 21/01/2014 This policy does apply to Medical/Dental Staff
AROMATHERAPY - CLINICAL GUIDELINE FOR MIDWIVES. January 2018
AROMATHERAPY - CLINICAL GUIDELINE FOR MIDWIVES V2 January 2018 1. Aim/Purpose of this Guideline 1.1. Aromatherapy is the use of essential oils, which can be administered by topical application via massage,
Bleeding / Pain after Renal Biopsy Guideline
Bleeding / Pain after Renal Biopsy Guideline This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances of the individual
Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.
Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy. Written by: Dr K Gajee, Consultant Microbiologist Date: June 2017 Approved by: Drugs & Therapeutics Committee
POLICY FOR TREATMENT OF LOWER RESPIRATORY TRACT INFECTIONS
POLICY F TREATMENT OF LOWER RESPIRATY TRACT INFECTIONS Written by: Dr M Milupi, Consultant Microbiologist Date: June 2018 Approved by: The Drugs & Therapeutics Committee Date: July 2018 Implementation
Pathology Service User Guide Haematology
Pathology Service User Guide Haematology St Richard s This section of the Pathology Service User Guide includes: Anticoagulant Therapy Information about the Anticoagulant Clinic Low Molecular Weight Heparin
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
Neutropenic Sepsis Guideline
Neutropenic Sepsis Guideline Neutropenic Sepsis Guideline - definitions Suspected or proven infection in a neutropenic patient is a MEDICAL EMERGENCY and is an indication for immediate assessment and prompt